BETHESDA, MdGeneral Motors Corp. is mailing information on the opportunity for a breast cancer risk assessment, available through the Study of Tamoxifen(Drug information on tamoxifen) and Raloxifene(Drug information on raloxifene) (STAR), to 140,000 of its active and retired salaried female employees. STAR researchers have enrolled more than 8,500 of a planned accrual of 22,000 postmenopausal women age 35 and older. The trial compares Evista (raloxifene) and Nolvadex (tamoxifen) for reducing breast cancer risk.
